FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older with pNET and epNET

The FDA approved cabozantinib for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).